0000000000914846

AUTHOR

Valentina Moressa

showing 2 related works from this author

Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal s…

2021

Familial Mediterranean fever (FMF) is characterized by self limited episodes of fever and polyserositis.1 MEFV gene en codes for a protein named Pyrin, which plays a pivotal role in the activation and secretion of IL-1.2 Daily colchicine is highly effective in preventing attacks in this disorder in a dose-related fashion.3 Many definitions of colchicine resistance are available in the literature. The European League Against Rheumatism (EULAR) guidelines defined resistance as one or more attacks per month in compliant patients who had been receiving the maxi mally tolerated dose for at least 6 months.4 A similar definition was confirmed by a recent consensus among experts.5 In the present na…

Longitudinal studybusiness.industryFamilial Mediterranean feverInterleukinDiseaseFamilial Mediterranea fevermedicine.diseaseSymptom Flare UpColchicine; Humans; Interleukin 1 Receptor Antagonist Protein; Longitudinal Studies; Symptom Flare Up; Familial Mediterranean FeverPersistence (computer science)Familial Mediterranean Feverchemistry.chemical_compoundInterleukin 1 Receptor Antagonist ProteinSettore MED/38 - Pediatria Generale E SpecialisticachemistryColchicine Humans Interleukin 1 Receptor Antagonist Protein Longitudinal Studies Symptom Flare Up Familial Mediterranean FeverImmunologyCOLCHICINE RESISTANCEImmunology and AllergyMedicineColchicineHumansLongitudinal StudiesbusinessColchicine
researchProduct

PReS-FINAL-2088: Risk of severe adverse events in juvenile idiopathic arthritis and pediatric-onset inflammatory bowel disease, treated with anti-tnf…

2013

Introduction: Severe adverse events have been described in children affected by Juvenile Idiopathic Arthritis (JIA) and Inflammatory Bowel Disease (IBD) treated with anti-tnf drugs. Objectives: To define the risk of severe adverse events in patients with JIA and IBD treated with anti-tnf drugs. Methods: This is a retrospective cohort study. All patients with JIA and IBD attending the "IRCCS Burlo Garofolo" of Trieste from 2000 to 2012 were enrolled. They were divided into 2 groups on the basis of the presence or absence of anti-tnf exposure. Severe adverse events were considered the followings: a) infections needing anti-tnf permanent suspension and/or hospitalization; b) autoimmune disease…

medicine.medical_specialtyPathologyPediatric onsetArthritismacromolecular substancesInflammatory bowel diseaseanti-TNF pediatric rheumatology arthritis adverse events inflammatory bowel diseaseRheumatologyinflammatory bowel diseaseInternal medicinemedicineImmunology and AllergyJuvenilePediatrics Perinatology and Child HealthPediatric rheumatologyAdverse effectbusiness.industryanti-TNFmedicine.diseaseadverse eventsdigestive system diseasesRheumatologypediatric rheumatologyarthritisPediatrics Perinatology and Child HealthPoster PresentationTumor necrosis factor alphabusiness
researchProduct